Abstract
One of the known risk factors for developing Alzheimer disease (AD) is hyperhomocysteinemia. The latter may result from mutations of the genes coding for three key enzymes involved in homocysteine metabolism (methylenetetrahydrofolate reductase [MTHFR], methionine synthase [MS], and cystathionine beta-synthase [CBS]). Although MTHFR and MS polymorphisms have been shown to be positively associated with AD in some populations, the relationship of the CBS gene with AD remains undefined. In order to evaluate whether AD is associated with CBS gene changes leading to decreased CBS activity and homocysteine accumulation, we genotyped the CBS 844ins68 mutation and VNTR polymorphisms of the CBS gene in 206 AD patients and 186 age-matched controls. A slight increase in both 844ins68 mutation and VNTR allele 19 frequencies was detected in the whole AD patient group, compared with controls. The division of AD patients and controls into three age-at-onset / age dependent subgroups ( < 65 years, 65-74 years, ≥ 75 years) revealed that the 844ins68 mutation and VNTR allele 19 are independent risk factors for AD development in subjects aged 75 years or more.
Keywords: alzheimer disease, cbs, 31 bp vntr, 844ins68 mutation, risk factors, age-at-onset/age
Current Alzheimer Research
Title: Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease
Volume: 1 Issue: 2
Author(s): Katrin Beyer, Jose I. Lao, Cristina Carrato, Ana Rodriguez-Vila, Pilar Latorre, Maria Mataro, Maria A. Llopis, Jose L. Mate and Aurelio Ariza
Affiliation:
Keywords: alzheimer disease, cbs, 31 bp vntr, 844ins68 mutation, risk factors, age-at-onset/age
Abstract: One of the known risk factors for developing Alzheimer disease (AD) is hyperhomocysteinemia. The latter may result from mutations of the genes coding for three key enzymes involved in homocysteine metabolism (methylenetetrahydrofolate reductase [MTHFR], methionine synthase [MS], and cystathionine beta-synthase [CBS]). Although MTHFR and MS polymorphisms have been shown to be positively associated with AD in some populations, the relationship of the CBS gene with AD remains undefined. In order to evaluate whether AD is associated with CBS gene changes leading to decreased CBS activity and homocysteine accumulation, we genotyped the CBS 844ins68 mutation and VNTR polymorphisms of the CBS gene in 206 AD patients and 186 age-matched controls. A slight increase in both 844ins68 mutation and VNTR allele 19 frequencies was detected in the whole AD patient group, compared with controls. The division of AD patients and controls into three age-at-onset / age dependent subgroups ( < 65 years, 65-74 years, ≥ 75 years) revealed that the 844ins68 mutation and VNTR allele 19 are independent risk factors for AD development in subjects aged 75 years or more.
Export Options
About this article
Cite this article as:
Beyer Katrin, Lao I. Jose, Carrato Cristina, Rodriguez-Vila Ana, Latorre Pilar, Mataro Maria, Llopis A. Maria, Mate L. Jose and Ariza Aurelio, Cystathionine Beta Synthase as a Risk Factor for Alzheimer Disease, Current Alzheimer Research 2004; 1 (2) . https://dx.doi.org/10.2174/1567205043332243
DOI https://dx.doi.org/10.2174/1567205043332243 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging
The thematic issue, Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging, aims to bridge the gap between advanced computational techniques and clinical practice in Alzheimer’s disease research. Alzheimer’s disease poses significant challenges in early diagnosis, disease progression monitoring, and predicting treatment efficacy. ...read more
Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies
The increasing burden of age-related neurodegenerative diseases demands an immediate and pressing need for research in all aspects, from molecular mechanisms to therapeutic interventions. The special issue in Current Alzheimer Research "Integrative Perspectives on Neurodegeneration and Aging: From Molecular Insights to Therapeutic Strategies" aims to highlight the summary of state-of-the-art ...read more
Leading Alzheimer Disease Prevention with Precision Health Strategies.
The rising number of patients with Alzheimer’s disease (AD) is a concerning reality in our society. Despite tremendous public-private efforts, finding an appropriate treatment for Alzheimer’s disease prevention has not been successful. One of the reasons behind this failure is the urge to find “a treatment that fits all sizes”, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Experts' Perspectives on the Current Practices and Gaps in the Management of
Dyslipidemia: A Report from The United Arab Emirates
New Emirates Medical Journal The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Expression, Purification and Characterization of Recombinant Canine FGF21 in Escherichia coli
Protein & Peptide Letters Patented Biomarkers of Peripheral Blood for the Early Detection of Cancer
Recent Patents on Biomarkers Plant Terpenes on Treating Cardiovascular and Metabolic Disease: A Review
Protein & Peptide Letters The Spatial QRS-T Angle: Implications in Clinical Practice
Current Cardiology Reviews Essentials of Daflon 500 mg: From Early Valve Protection to Long-Term Benefits in the Management of Chronic Venous Disease
Current Pharmaceutical Design Parathyroid Hypertension: A Rare, but Curable form of Secondary Hypertension
Current Hypertension Reviews Mining the Genome for Susceptibility to Complex Neurological Disorders
Current Molecular Medicine Crocetin: an Agent Derived from Saffron for Prevention and Therapy for Cancer
Current Pharmaceutical Biotechnology Role of Cardiolipin in Mitochondrial Diseases and Apoptosis
Current Medicinal Chemistry Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism HDAC3 Impairs Cardiac Function in Chronic Heart Failure Rats <i>via</i> Mediating MicroRNA-26b-3p to Target High Mobility Group AT-Hook 2
Current Medicinal Chemistry Investigating Biomarkers for COVID-19 Morbidity and Mortality
Current Topics in Medicinal Chemistry Calcium Channel Blockers in Obesity-Related Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Physiopathological Roles of P2X Receptors in the Central Nervous System
Current Medicinal Chemistry Ivabradine in the Management of COVID-19-related Cardiovascular Complications: A Perspective
Current Pharmaceutical Design Editorial (Thematic Issue: Development of Natural Products as Anti-Parasitic Agents)
Current Clinical Pharmacology To Cardiovascular Disease and Beyond: New Therapeutic Perspectives of Statins in Autoimmune Diseases and Cancer
Current Drug Targets